Moliya
Moliya
Bosh sahifaRDY • NYSE
Dr Reddy's Laboratories Ltd
14,54 $
Dastlabki sotuv:
14,40 $
(0,96%)-0,14
Yopilgan:12-mar, 4:20:41 (GMT-4) · USD · NYSE · Ogohlantirish
AksiyalarAQSH qimmatli qogʻoziBosh shtabi: IN
Yopilish kursi
14,51 $
Kunlik diapazon
14,45 $ - 14,55 $
Yillik diapazon
12,26 $ - 16,17 $
Bozor kapitalizatsiyasi
11,90 mlrd USD
Oʻrtacha hajm
1,97 mln
Narx/foyda
19,69
Dividend daromadliligi
0,63%
Yangiliklarda
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
(INR)dek, 2025Y/Y qiyosi
Daromad
87,27 mlrd4,41%
Joriy xarajat
32,48 mlrd7,03%
Sof foyda
12,10 mlrd-14,40%
Sof foyda marjasi
13,86-18,04%
Har bir ulushga tushum
14,77-12,79%
EBITDA
19,54 mlrd-16,58%
Amaldagi soliq stavkasi
22,90%
Jami aktivlari
Jami passivlari
(INR)dek, 2025Y/Y qiyosi
Naqd pul va qisqa investitsiyalar
82,59 mlrd37,83%
Jami aktivlari
562,90 mlrd17,01%
Jami passivlari
187,14 mlrd17,34%
Umumiy kapital
375,76 mlrd
Tarqatilgan aksiyalar
832,57 mln
Narxi/balansdagi bahosi
0,03
Aktivlardan daromad
6,48%
Kapitaldan daromad
8,29%
Naqd pulning sof oʻzgarishi
(INR)dek, 2025Y/Y qiyosi
Sof foyda
12,10 mlrd-14,40%
Operatsiyalardan naqd pul
10,91 mlrd64,77%
Sarmoyadan naqd pul
-10,29 mlrd-88,57%
Moliyadan naqd pul
7,78 mlrd1 218,14%
Naqd pulning sof oʻzgarishi
8,75 mlrd400,92%
Boʻsh pul
-672,75 mln-26,52%
Haqida
Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company based in Hyderabad, with U.S. headquarters in East Brunswick, New Jersey. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology. Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe. By 2007, Dr. Wikipedia
Tashkil etilgan
1984
Xodimlar soni
27 811
Yana
Bu sizni qiziqtirishi mumkin
Bu roʻyxat oxirgi qidiruvlar, kuzatilgan aksiyalar va boshqa faoliyatdan tuzilgan. Batafsil

Barcha axborotlar faqat maʼlumot sifatida “shundayligicha” taqdim etilgan, ulardan moliyaviy maslahat sifatida foydalanmang, ular savdo maqsadlari yoki investitsiya, soliq, yuridik, buxgalteriya yoki boshqa turdagi maslahat emas. Google investitsiya borasida maslahatchi emas, bu roʻyxatdagi kompaniyalar yoki ularning aksiyalari borasida hech qanday nuqtai nazar, tavsiya yoki fikr bildirmaydi. Har qanday savdoni boshlashdan oldin broker yoki moliyaviy vakil bilan maslahatlashib, narxlarni tekshiring. Batafsil
Aloqador qidiruvlar
Qidiruv
Qidiruv maydonini tozalash
Qidiruvni yopish
Google ilovalari
Asosiy menyu